| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | 7a |
| Uniprot No | Q9UPZ6 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-1657aa |
| 氨基酸序列 | MGLQARRWASGSRGAAGPRRGVLQLLPLPLPLPLLLLLLLRPGAGRAAAQGEAEAPTLYLWKTGPWGRCMGDECGPGGIQTRAVWCAHVEGWTTLHTNCKQAERPNNQQNCFKVCDWHKELYDWRLGPWNQCQPVISKSLEKPLECIKGEEGIQVREIACIQKDKDIPAEDIICEYFEPKPLLEQACLIPCQQDCIVSEFSAWSECSKTCGSGLQHRTRHVVAPPQFGGSGCPNLTEFQVCQSSPCEAEELRYSLHVGPWSTCSMPHSRQVRQARRRGKNKEREKDRSKGVKDPEARELIKKKRNRNRQNRQENKYWDIQIGYQTREVMCINKTGKAADLSFCQQEKLPMTFQSCVITKECQVSEWSEWSPCSKTCHDMVSPAGTRVRTRTIRQFPIGSEKECPEFEEKEPCLSQGDGVVPCATYGWRTTEWTECRVDPLLSQQDKRRGNQTALCGGGIQTREVYCVQANENLLSQLSTHKNKEASKPMDLKLCTGPIPNTTQLCHIPCPTECEVSPWSAWGPCTYENCNDQQGKKGFKLRKRRITNEPTGGSGVTGNCPHLLEAIPCEEPACYDWKAVRLGNCEPDNGKECGPGTQVQEVVCINSDGEEVDRQLCRDAIFPIPVACDAPCPKDCVLSTWSTWSSCSHTCSGKTTEGKQIRARSILAYAGEEGGIRCPNSSALQEVRSCNEHPCTVYHWQTGPWGQCIEDTSVSSFNTTTTWNGEASCSVGMQTRKVICVRVNVGQVGPKKCPESLRPETVRPCLLPCKKDCIVTPYSDWTSCPSSCKEGDSSIRKQSRHRVIIQLPANGGRDCTDPLYEEKACEAPQACQSYRWKTHKWRRCQLVPWSVQQDSPGAQEGCGPGRQARAITCRKQDGGQAGIHECLQYAGPVPALTQACQIPCQDDCQLTSWSKFSSCNGDCGAVRTRKRTLVGKSKKKEKCKNSHLYPLIETQYCPCDKYNAQPVGNWSDCILPEGKVEVLLGMKVQGDIKECGQGYRYQAMACYDQNGRLVETSRCNSHGYIEEACIIPCPSDCKLSEWSNWSRCSKSCGSGVKVRSKWLREKPYNGGRPCPKLDHVNQAQVYEVVPCHSDCNQYLWVTEPWSICKVTFVNMRENCGEGVQTRKVRCMQNTADGPSEHVEDYLCDPEEMPLGSRVCKLPCPEDCVISEWGPWTQCVLPCNQSSFRQRSADPIRQPADEGRSCPNAVEKEPCNLNKNCYHYDYNVTDWSTCQLSEKAVCGNGIKTRMLDCVRSDGKSVDLKYCEALGLEKNWQMNTSCMVECPVNCQLSDWSPWSECSQTCGLTGKMIRRRTVTQPFQGDGRPCPSLMDQSKPCPVKPCYRWQYGQWSPCQVQEAQCGEGTRTRNISCVVSDGSADDFSKVVDEEFCADIELIIDGNKNMVLEESCSQPCPGDCYLKDWSSWSLCQLTCVNGEDLGFGGIQVRSRPVIIQELENQHLCPEQMLETKSCYDGQCYEYKWMASAWKGSSRTVWCQRSDGINVTGGCLVMSQPDADRSCNPPCSQPHSYCSETKTCHCEEGYTEVMSSNSTLEQCTLIPVVVLPTMEDKRGDVKTSRAVHPTQPSSNPAGRGRTWFLQPFGPDGRLKTWVYGVAAGAFVLLIFIVSMIYLACKKPKKPQRRQNNRLKPLTLAYDGDADM |
| 预测分子量 | 185,3 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于SARS-CoV-2 7a重组蛋白的3篇参考文献示例(注：文献为示例性内容，实际引用需核实准确性)：
---
1. **文献名称**: "Structural and functional analysis of the SARS-CoV-2 accessory protein 7a"
**作者**: Zhang, Y., et al.
**摘要**: 本研究通过X射线晶体学解析了SARS-CoV-2 7a蛋白的晶体结构，发现其与宿主细胞ACE2受体存在潜在相互作用，并证明7a蛋白可通过诱导细胞凋亡促进病毒释放。
2. **文献名称**: "Recombinant expression of SARS-CoV-2 7a protein in E. coli and its application in serological assays"
**作者**: Liu, X., et al.
**摘要**: 报道了在大肠杆菌中高效表达重组7a蛋白的方法，纯化后蛋白可用于ELISA检测COVID-19患者血清中的特异性抗体，验证其作为诊断抗原的潜力。
3. **文献名称**: "SARS-CoV-2 7a protein antagonizes interferon signaling by blocking STAT1 phosphorylation"
**作者**: Kim, D., et al.
**摘要**: 发现重组7a蛋白通过抑制STAT1磷酸化干扰I型干扰素信号通路，揭示其在病毒免疫逃逸中的关键作用，为治疗策略提供新靶点。
---
如需真实文献，建议在PubMed或Google Scholar中检索关键词："SARS-CoV-2 7a protein recombinant" 或 "7a accessory protein function"。
7a recombinant protein, a product of advanced genetic engineering techniques, represents a class of biologically active molecules designed for diverse applications in biomedicine and research. The development of recombinant proteins emerged from breakthroughs in molecular biology during the 1970s-1980s, enabling precise manipulation of DNA sequences to express target proteins in heterologous host systems. The "7a" designation typically refers to a specific isoform or engineered variant within a protein family, often characterized by unique structural modifications or enhanced functional properties compared to native counterparts.
This protein is synthesized through recombinant DNA technology, where the gene encoding the 7a sequence is cloned into expression vectors and introduced into host organisms such as E. coli, yeast, or mammalian cell lines. The choice of production system depends on required post-translational modifications and intended applications. Rigorous purification processes ensure high purity and bioactivity, critical for both therapeutic and analytical uses.
The scientific rationale behind 7a protein engineering often involves optimizing stability, binding affinity, or reduced immunogenicity for clinical applications. In therapeutic contexts, it may serve as a targeted biologic drug, diagnostic biomarker, or vaccine component. Researchers utilize 7a recombinant protein as a molecular tool for studying protein-protein interactions, cellular signaling pathways, or disease mechanisms. Recent advancements in structural biology and computational protein design have accelerated the development of such engineered variants, allowing precise customization of functional domains. Current challenges include maintaining cost-effective production scales and ensuring consistent batch-to-batch quality, particularly for GMP-grade manufacturing. Ongoing research focuses on improving expression yields and modifying glycosylation patterns to enhance therapeutic efficacy.
×
